

Eliminating Hepatitis C Treatment Restrictions for DHCF Beneficiaries



July 22, 2020

Goal: Remove Restrictions to Hepatitis C Curative Treatment

- Eliminating hepatitis C in the District is a shared goal among DC Health and DHCF, and enabling access to curative treatment is a priority for achieving equitable outcomes for Medicaid beneficiaries.
- DC's Medicaid program imposes variable restrictions across FFS and MCO programs for prescribing hepatitis C curative treatment:
 - **Fibrosis score requirements**
 - Abstinence requirements
 - Specialist requirements
 - Prior authorization
- Removal of fibrosis score restrictions is now financially feasible since pricing competition has drastically reduced the cost of hepatitis C curative treatment.

Proposed Timeline for Removal of Hepatitis C Treatment Restrictions

1. Eliminate minimum fibrosis score requirement across FFS and MCO programs – January 1, 2021

- Currently working with actuary to ensure consideration of the change and impact to MCO rates.

2. Elimination of additional restrictions – for consideration for FY 2022:

- Eliminate the abstinence requirement.
- Eliminate the requirement that medications be prescribed by or in consultation with a specialist.
- Eliminate prior authorization.